Technical Analysis for IMGN - ImmunoGen, Inc.

Grade Last Price % Change Price Change
grade C 3.17 -0.94% -0.03
IMGN closed down 0.94 percent on Friday, September 13, 2019, on 82 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical IMGN trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Jack-in-the-Box Bullish Bullish Swing Setup -0.94%
Upper Bollinger Band Walk Strength -0.94%
Above Upper BB Strength -0.94%
Overbought Stochastic Strength -0.94%
Upper Bollinger Band Touch Strength -0.94%
Expansion Breakout Bullish Swing Setup -1.86%

Older signals for IMGN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology. Its product candidates include Trastuzumab emtansine, a Phase III clinical trial product for HER2+ metastatic breast cancer; lorvotuzumab mertansine, which is in Phase II clinical trial for the treatment of diagnosed metastatic small-cell lung cancer, as well as in a Phase I clinical trial for the treatment of multiple myeloma; IMGN853, a Phase I clinical trial product that targets over-expressed folate receptor 1 in ovarian cancer and other types of solid tumors, including non-small cell lung cancer; and IMGN529, a product in Phase I clinical trial for treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia. The company's compounds in earlier-stage of development comprise SAR3419, a Phase II clinical trial product to treat CD19-expressing B-cell malignancies, such as NHL and B-cell acute lymphoblastic leukemia; BT-062, a Phase I product, which targets CD138 antigen found on multiple myeloma and various solid tumors; SAR650984, a Phase I clinical trial product for CD38-targeting hematological malignancies; SAR566658, a Phase I clinical trial product for DS6-expressing solid tumors; BAY 94-9343, a Phase I clinical trial product for mesothelin-expressing solid tumors; and Amgen 1 and Amgen 2, which are phase I clinical trial compounds. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Genentech, Inc; Sanofi; and Hoffman-La Roche Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Biotechnology Clinical Medicine Drugs Solid Tumors Monoclonal Antibodies Non Small Cell Lung Cancer Ovarian Cancer Lymphoma Multiple Myeloma Chronic Lymphocytic Leukemia Antibody Drug Conjugates Clinical Trial Product Metastatic Breast Cancer NHL Amgen Immunogen Its Its Products Metastatic Small Cell Lung Cancer
Is IMGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 9.84
52 Week Low 1.76
Average Volume 1,838,470
200-Day Moving Average 3.3295
50-Day Moving Average 2.598
20-Day Moving Average 2.799
10-Day Moving Average 2.937
Average True Range 0.1656
ADX 31.77
+DI 30.0095
-DI 9.3203
Chandelier Exit (Long, 3 ATRs ) 2.7832
Chandelier Exit (Short, 3 ATRs ) 2.9868
Upper Bollinger Band 3.2378
Lower Bollinger Band 2.3602
Percent B (%b) 0.92
BandWidth 31.354055
MACD Line 0.1539
MACD Signal Line 0.1079
MACD Histogram 0.046
Fundamentals Value
Market Cap 284.02 Million
Num Shares 89.6 Million
EPS -1.22
Price-to-Earnings (P/E) Ratio -2.60
Price-to-Sales 5.58
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.41
Resistance 3 (R3) 3.42 3.35 3.37
Resistance 2 (R2) 3.35 3.29 3.35 3.36
Resistance 1 (R1) 3.26 3.25 3.23 3.25 3.34
Pivot Point 3.19 3.19 3.17 3.19 3.19
Support 1 (S1) 3.10 3.13 3.07 3.09 3.00
Support 2 (S2) 3.03 3.09 3.03 2.98
Support 3 (S3) 2.94 3.03 2.97
Support 4 (S4) 2.93